Sun Pharma to acquire Organon for $11.75 billion
after close1 source ↓written by the desknot a recommendation
- all-cash deal
- $11.75 billion
- priced
- $14 per share
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Company in an $11.75 billion all-cash deal, priced at $14 per share. The transaction is expected to close within six to nine months and will be financed through a combination of cash surplus and committed bank financing.
This acquisition marks a significant strategic move for Sun Pharma, potentially enhancing its product portfolio and market presence. Investors will be keenly watching the integration roadmap and financial implications discussed during the recent investor call.
Not investment advice. For informational purposes only.